EirGenix battles cancer, Covid-19 with breakthrough biologics
- With the largest biopharmaceutical manufacturing capacity in Taiwan, EirGenix has helped clients with biological products, from preclinical development to commercial manufacturing
Country Business Reports interviews and articles by Discovery Reports
As one of Taiwan’s top biopharmaceutical companies, EirGenix strongly believes that health should be for all. The company stands by this principle as it aids clients in creating biosimilars, biobetters and new drugs, along with manufacturing its own line of life-saving biologics.
EirGenix offers contract services for biologics such as process development, analytical services and current Good Manufacturing Practice (cGMP) production in microbial and mammalian systems. It has helped clients with biological products from preclinical development to commercial manufacturing, including aiding in Taiwan’s first Covid-19 vaccine approved for emergency use.
EirGenix has also been a leader in the development of HER2 breast cancer biosimilars. It has formed a licensing agreement with Sandoz to globally market its trastuzumab biosimilar EG12014, which yielded positive results in global phase three clinical trials and has been submitted to the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval.
EirGenix’s facilities have been inspected and certified by Taiwan’s FDA as Pharmaceutical Inspection Co-operation Scheme GMP-compliant. In 2020, EirGenix was the first biopharmaceutical facility in Taiwan to receive approval from Japan’s Pharmaceutical and Medical Device Agency. With its Biologics License Application and Marketing Authorisation Application submitted to the US FDA and EMA, EirGenix is expecting pre-approval inspections from the agencies this year.
“We strive to be a highly reliable source for our clients, but what’s most important is to consider the health of the whole world,” says Dr Liu Lee-cheng, founder, chairman and president. “We possess the largest biopharmaceutical manufacturing capacity in Taiwan that continues to expand.”
The company’s success has even attracted the attention of Foxconn founder Terry Guo, who invested more than US$175 million in EirGenix last year. With the influx of new capital, EirGenix will accelerate its development plans that include the addition of products to its pipeline through in-licensing and collaboration agreements. It will also fast track its expansion, which involves additional service offerings, capacity maximisation of facilities, and construction of a large-scale manufacturing facility with a total bioreactor capacity of 150,000 litres.
